Tissue factor pathway inhibitor and anti-FXa kinetic profiles of a new low-molecular-mass heparin, Bemiparin, at therapeutic subcutaneous doses

Blood Coagulation and Fibrinolysis

Volumn 9, Issue 2, 1998, Pages 137-141

  Falkon, L ^a,b,c,d   Gari M ^a,b,c   Barbanoj, M ^a,b   Amiral, J ^a,b,c   Fontcuberta, J ^a,b  

^a Unitat d Hemostasia i Trombosis IIB Sant Pau   (Spain)

^b Hospitaldela SantaCreuiSantPau   (Spain)

^c Serbia Research Laboratory   (France)

^d Hospital de la Santa Cren I Sant Pan   (Spain)

Author keywords

Low molecular mass heparin; Pharmacokinetics; Tissue factor pathway inhibitor

Indexed keywords

BEMIPARIN; BLOOD CLOTTING FACTOR 10A INHIBITOR; LOW MOLECULAR WEIGHT HEPARIN; TISSUE FACTOR PATHWAY INHIBITOR; UNCLASSIFIED DRUG;

ADULT; ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; DOSE RESPONSE; HEPARINIZATION; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL;

EID: 0031977005     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-199803000-00004     Document Type: Article

References (24)

1. Hirsh J, Levine MN. Low molecular weight heparin. Blood 1992; 79: 1-17.
2. Samama MM, Bara L, Gerotziafas GT. Mechanisms of the antithrombotic activity of low molecular weight heparins (LMWHs). Haemostasis 1994; 24: 105-117.
3. Holmer E, Mattsson C, Nilsson S. Anticoagulant and antithrombotic effects of heparin and low molecular weight heparin fragments in rabbits. Tbromb Res 1982; 25: 613-625.
4. Thomas DP, Merton RE, Barrowcliffe TW, Thunberg L, Lindhai U. Effects of heparin oligosaccharides with high affinity for antithrombin III in experimental venous thrombosis. Thromb Haemostas 1982; 47: 244-248.
5. Walenga JM, Fareed J, Petitou M, Samama MM, Lormeau JC, Choay J. Intravenous antithrombotic activity of a synthetic heparin pentasaccharide in a human 'serum induced stasis thrombosis model. Thromb Res 1986; 43: 243-248.
6. Walenga JM, Petitou M, Lormeau JC, Samama MM, Fareed J, Choay J. Antithrombotic activity of a synthetic heparin pentasaccharide in a rabbit stasis model using different thrombogenic challenges. Thromb Res 1987; 46: 187-198.
7. Kakkar W. Effectiveness and safety of low molecular weight heparins (LMWH) in the prevention of venous thromboembolism (VTE). Thromb Haemost 1995; 74: 364-368.
8. Hirsh J, Siragusa S, Cosmi B, Ginsberg JS. Low molecular weight heparins (LMWH) in the treatment of patients with acute venous thromboembolism. Thromb Haemost 1995; 74: 360-363.
9. Sandset PM, Abildgaard U, Larsen MI. Heparin induces release of extrinsic pathway inhibitor. Thromb Res 1988; 50: 803-813.
10. Broze GJ Jr. Tissue factor pathway inhibitor. Thromb Haemost 1995; 74: 90-93.
11. Wun TC. Lipoprotein-associated coagulation inhibitor (LACI) is a cofactor for heparin: synergistic anticoagulant action between LACI and sulfated polysaccharides. Blood 1992; 79: 430-438.
12. Novotny WF, Brown SG, Miletich JP, Rader DJ, Broze GJ Jr. Plasma antigen levels of lipoprotein-associated coagulation inhibitor in patient samples. Blood 1991; 78: 387-393.
13. Marsh N. Annotation: Does heparin stimulate fibrinolysis. BrJHaematol 1990; 76: 163-167.
14. Lane DA, Pejler G, Flunn AM, Thompson EA, Lindhal U. Neutralization of heparin-related saccharides by histidine-rich glycoprotein and platelet factor IV. ] Biol Chem 1983; 261: 3980-3987.
15. Falkon L, Saenz-Campos D, Antonijoan R, Martin S, Barbanoj M, Fontcuberta J. Unavailability and pharmacokinetics of a new low molecular weight heparin (RO-11). A three way cross-over study in healthy volunteers. Thromb Res 1995; 78: 77-86.
16. Shumaker RC. PK cale: a basic interactive computer program for statistical and pharmacokinetic analysis of data. Drug Metab Rev 1986; 17: 331-348.
17. Yamaoka K, Naragawa T, Uno T. Statistical moments in pharmacokinetics. / Pbarmacokinet Biopharm 1978; 6: 547-558.
18. Valentin S, Ostergaard P, Kristensen H, Norfang O. Synergism between full length TFPI and heparin. Blood Coag Fibrinol 1992; 3: 221-222.
19. Falkon L, Garf M, Sàenz-Campos D, Antonijoan R, Barbanoj M, Fontcuberta J. Kinetic behaviour of the TFPI and anti-FXa effects, after the injection of a LMWH (RO-11) in healthy subjects. Thromb Haemost 1995; 73: 728-729.
20. Hoppensteadt DA, Jeske W, Farced J. Bermes Jr EW. The role of tissue factor pathway inhibitor in the mediation of the antithrombotic action of heparin and low molecular weight heparin. Blood Coag Fibrinol 1995; 6: 57-64.
21. Novotny WF, Girard TJ, Miletich JP, Broze GJ. Purification and characterization of the lipoproteinassociated coagulation inhibitor from human plasma. / Biol Chem 1989; 264: 18832-19937.
22. Hubbard AR, Jennings CA. Inhibition of the tissue factor-factor VII complex: involvment of factor Xa and lipoproteins. Thromb Res 1987; 46: 527-537.
23. Warn-Cramer BJ, Maki SL, Zivelin A, Rapaport SI. Partial purification and characterization of extrinsic pathway inhibitor (the factor Xa-dependent plasma inhibitor of factor FVIIa/tissue factor). Thromb Res 1987; 48: 11-22.
24. Hansen JB, Sandset PM, Huseby KR, Huseby NE, Nordoy A. Depletion of intravascular pools of tissue pathway factor inhibitor (TFPI) during repeated or continuous intravenous infusion of heparin in man. Thromb Haemost 1996; 76: 703-709.